Retracted: Prognostic Comparison between cTACE and H101-TACE in Unresectable Hepatocellular Carcinoma (HCC): A Propensity-Score Matching Analysis

Retracted: Prognostic Comparison between cTACE and H101-TACE in Unresectable Hepatocellular Carcinoma (HCC): A Propensity-Score Matching Analysis

Saved in:

Bibliographic Details
Main Author:	Applied Bionics and Biomechanics
Format:	Article
Language:	English
Published:	Wiley 2023-01-01
Series:	Applied Bionics and Biomechanics
Online Access:	http://dx.doi.org/10.1155/2023/9813798
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Prognostic Comparison between cTACE and H101-TACE in Unresectable Hepatocellular Carcinoma (HCC): A Propensity-Score Matching Analysis
by: Man Yao, et al.
Published: (2022-01-01)

TACE Combined with Lenvatinib-PD-1 Versus TACE Monotherapy as Conversion Therapy Before Liver Resection in Unresectable Hepatocellular Carcinoma: A Retrospective, Propensity Score Matching Study
by: Lu C, et al.
Published: (2025-07-01)

Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis.
by: Lei Liu, et al.
Published: (2014-01-01)

Survival in patients with unresectable hepatocellular carcinoma: TCC cocktail plus TACE vs TACE alone prospective randomized clinical trial
by: Jie Li, et al.
Published: (2025-07-01)

Efficacy and safety of D-TACE followed by D-RFA for unresectable large hepatocellular carcinoma
by: Qingqing Pang, et al.
Published: (2025-07-01)

Conversion therapy with TACE, TKIs, and ICIs for unresectable BCLC stage B and C hepatocellular carcinoma
by: Zhuoran Wang, et al.
Published: (2025-06-01)

Outcome of adding percutaneous transhepatic cholangial drainage to DEB-TACE in patients with unresectable cholangiocarcinoma with obstructive jaundice: comparison with sole DEB-TACE
by: Jiajia Xu, et al.
Published: (2025-08-01)

Correction: Conversion therapy with TACE, TKIs, and ICIs for unresectable BCLC stage B and C hepatocellular carcinoma
by: Zhuoran Wang, et al.
Published: (2025-06-01)

DCP as a biomarker for TACE efficacy in hepatocellular carcinoma
by: Hui Xie, et al.
Published: (2025-07-01)

A Machine Learning Model for Predicting Prognosis in HCC Patients With Diabetes After TACE
by: Wu L, et al.
Published: (2025-01-01)

Unresectable ectopic hepatocellular carcinoma in the left sub-diaphragmatic area and retroperitoneum treated with TACE: case report and literature review
by: Chao-Bang Xie, et al.
Published: (2025-12-01)

First-line treatment of hepatocellular carcinoma: a propensity-matched analysis of tyrosine kinase inhibitors combined with TACE, with or without PD-1 inhibitors
by: Yanjun Shen, et al.
Published: (2025-05-01)

Efficacy of combined TAE, HAIC, targeted, and immunotherapy in unresectable HCC: a multicenter propensity score matching study
by: Cheng Zhang, et al.
Published: (2025-07-01)

Safety and efficacy of TACE combined with immune checkpoint inhibitors plus molecular targeted therapies in older adults with unresectable hepatocellular carcinoma
by: Xin Hong, et al.
Published: (2025-07-01)

Optimizing TACE for Hepatocellular Carcinoma: The Impact of Intra-Arterial Contrast Enhanced Ultrasound
by: Linda Galasso, et al.
Published: (2025-05-01)

Treatments of transarterial chemoembolization (TACE), stereotactic body radiotherapy (SBRT) and immunotherapy reshape the systemic tumor immune environment (STIE) in patients with unresectable hepatocellular carcinoma
by: Cai-Ning Zhao, et al.
Published: (2025-02-01)

Longitudinal CE-MRI-based Siamese network with machine learning to predict tumor response in HCC after DEB-TACE
by: Nan Wei, et al.
Published: (2025-08-01)

Pressure Gradient-Driven Embolization b-TACE for HCC: Technical and Diagnostic Step-by-Step Procedural Guide and Literature Review
by: Bianca Rocco, et al.
Published: (2025-07-01)

Efficacy and safety analysis of DEB-TACE for hepatocellular carcinoma with portal vein tumor thrombosis
by: Yan Zhang, et al.
Published: (2025-06-01)

Application of Nanotechnology in TACE Treatment of Liver Cancer
by: Yao L, et al.
Published: (2025-08-01)

Donafenib versus sorafenib in triple therapy for unresectable hepatocellular carcinoma: a propensity score-matched multicenter analysis
by: Yaohong Wen, et al.
Published: (2025-04-01)

Prognostic impact of tace combined with sorafenib or lenvatinib followed by regorafenib in recurrent hepatocellular carcinoma after liver transplantation: a retrospective study
by: Zhao-dan Ye, et al.
Published: (2025-07-01)

A Transcriptomic Biomarker for Predicting the Response to TACE Correlates with the Tumor Microenvironment and Radiomics Features in Hepatocellular Carcinoma
by: Wang C, et al.
Published: (2024-11-01)

The role of TACE in the era of immune-targeted therapy for hepatocellular carcinoma: a meta-analysis based on PSM
by: Jiahao Li, et al.
Published: (2025-04-01)

Retracted: The Relevance of Interventional Time and Clinical Outcomes in Patients with NSTEMI Based on the GRACE Score
by: Applied Bionics and Biomechanics
Published: (2023-01-01)

Retracted: Ferroptosis-Related Long Noncoding RNAs as Prognostic Marker for Colon Adenocarcinoma
by: Applied Bionics and Biomechanics
Published: (2023-01-01)

Transient hepatic intensity differences: correlations with treatment outcomes and adverse events following DEB-TACE in hepatocellular carcinoma
by: Noble Chibuike Opara, et al.
Published: (2025-08-01)

Case Report: Durable complete response of advanced-stage hepatocellular carcinoma to DEB−TACE combined with lenvatinib and camrelizumab
by: Baiguo Xu, et al.
Published: (2025-06-01)

Molecular subtyping combined with multiomics analysis to study correlation between TACE refractoriness and tumor stemness in hepatocellular carcinoma
by: Qifan He, et al.
Published: (2025-02-01)

A CT-Based Deep Learning Radiomics Scoring System for Predicting the Prognosis to Repeat TACE in Patients with Hepatocellular Carcinoma: A Multicenter Cohort Study
by: Dai Y, et al.
Published: (2025-07-01)

Niacin‐mediated Tace activation ameliorates CMT neuropathies with focal hypermyelination
by: Alessandra Bolino, et al.
Published: (2016-10-01)

Retracted: A Novel Prognostic Stratified System Based on Tumor Budding and the Cell Nest Size in Ureter Urothelial Carcinoma
by: Applied Bionics and Biomechanics
Published: (2023-01-01)

Ultrasound-guided percutaneous microwave ablation for metabolic-associated fatty liver disease-related hepatocellular carcinoma (HCC) versus hepatitis virus B-related HCC: a propensity score matching study
by: Yannan Qiao, et al.
Published: (2024-12-01)

Clinical efficacy of TACE using coil or gelatin sponge combined with targeted therapy in the treatment of giant hepatocellular carcinoma with arterioportal fistulas
by: Zhijuan Wu, et al.
Published: (2025-05-01)

ALBI Grade Analyses of TACE Combined with Anti-Angiogenesis Therapies Plus PD-1 Inhibitors versus Anti-Angiogenesis Therapies Plus PD-1 Inhibitors in Advanced HCC
by: Hong X, et al.
Published: (2024-12-01)

TACE Versus TARE in the Treatment of Liver-Metastatic Breast Cancer: A Systematic Review
by: Charalampos Lalenis, et al.
Published: (2025-07-01)

Prognostic Value of the SII-PNI Score in Unresectable HCC Treated with Transcatheter Arterial Chemoembolization Combined with Lenvatinib and PD-1 Inhibitors
by: Wei SM, et al.
Published: (2025-06-01)

Retracted: Ferroptosis in Macrophage Impairment in Sepsis
by: Applied Bionics and Biomechanics
Published: (2023-01-01)

A controlled study of Gd-EOB-DTPA-enhanced MRI compared with enhanced CT in assessing lesion status after TACE for hepatocellular carcinoma
by: Qichao Cheng, et al.
Published: (2025-07-01)

Effectiveness of a nurse-led pain management model following TACE: a retrospective analysis
by: Yili Qu, et al.
Published: (2025-07-01)